NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading PRCT? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story in the healthcare sector. PRCT is currently facing challenges, including being loss-making and having weak recent financial performance, but it operates in a sector with positive momentum.
The market appears to have a low expectations gap, indicating that current valuations are justified given the company's financial struggles. PRCT is trading at a premium compared to its peers, suggesting that investors are cautious but not overly pessimistic.
Management's priorities include achieving specific revenue and gross margin targets, but the path to reducing adjusted EBITDA losses is challenging. Recent financial performance has been weak, and there is a notable risk of missing future earnings expectations.
The thesis hinges on PRCT's ability to meet its revenue and margin targets while navigating the potential volatility of the healthcare sector. Key factors include the performance of sector bellwethers and management's guidance in upcoming earnings calls.
Over the next 1 to 3 years, PRCT's outlook will depend on its execution against management's targets and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting or exceeding this growth rate supports management's full-year revenue guidance. It shows strong demand for their products.
Confirms:Q2 revenue growth of 27% or more compared to Q2 2025.
Disproves:Q2 revenue growth falls below 20% compared to Q2 2025.
Why it matters: Faster growth in the sector may help PROCEPT's market position and increase revenue.
Confirms one read:Health Care sector revenue growth reported above 10% year over year.
Confirms the other:Health Care sector revenue growth reported below 5% year over year.
Why it matters: A drop below median growth could signal weakening in the health care sector overall.
Confirms:Sector revenue growth reported below its median.
Disproves:Sector revenue growth stays above its median.
Why it matters: Keeping this margin shows good cost control. It helps meet profit goals.
Confirms:Gross margin reported at 65% or higher for Q2.
Disproves:Gross margin drops below 63% for Q2.
Why it matters: A smaller loss shows better efficiency. It means progress toward making money.
Confirms:Adjusted EBITDA loss narrows to $20 million or less in Q2.
Disproves:Adjusted EBITDA loss widens beyond $25 million in Q2.
Why it matters: News about this trial can change future products and market position.
Confirms one read:Good news or milestones from the WATER IV trial.
Confirms the other:Negative updates or delays in the WATER IV trial.
